Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
02:51pm, Friday, 29'th Jul 2022 Zacks Investment Research
Zoetis (ZTS) is set to report impressive earnings and revenues and provide an update on its pipeline when it releases second-quarter 2022 results.
What is in Store for Regeneron (REGN) This Earnings Season?
02:20pm, Friday, 29'th Jul 2022 Zacks Investment Research
Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.
Assertio (ASRT) to Report Q2 Earnings: What's in the Cards?
04:20pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Assertio Holdings' (ASRT) second-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
03:40pm, Thursday, 28'th Jul 2022 Zacks Investment Research
On Novavax's (NVAX) second-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
Is a Beat in Store for Gilead (GILD) in This Earnings Season?
02:10pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) second-quarter 2022 results.
Taro Pharmaceutical (TARO) Lags Q1 Earnings Estimates
11:05pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Taro (TARO) delivered earnings and revenue surprises of -56.47% and 4.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02:02pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis to hold second quarter 2022 financial results webcast
07:05am, Wednesday, 27'th Jul 2022
Webcast scheduled for Tuesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
What's in Store for United Therapeutics' (UTHR) Q2 Earnings?
02:13pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
United Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso, Remodulin and Orenitram in the second quarter, as these constitute a vast majority of the total revenues.
Where Ionis Pharmaceuticals Stands With Analysts
01:47pm, Tuesday, 26'th Jul 2022 Benzinga
Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
2
1
1
0
Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why
04:04pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the internation
Verve (VERV) Up on Gene Editing Collaboration With Vertex
03:34pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Verve Therapeutics (VERV) enters into a four-year collaboration with Vertex Therapeutics to develop a gene-editing program targeted at liver disease for an upfront payment of $60 million.
Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment
02:40pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 20
Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment
01:14pm, Thursday, 21'st Jul 2022
Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 20
Ionis (IONS) Partner to Begin Phase III Study on Kidney Drug
03:14pm, Tuesday, 12'th Jul 2022 Zacks Investment Research
Ionis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the treatment of IgAN after announcing positive data from a phase II study.
